A Randomized, Double-Blind, Placebo-Controlled Clinical Trial Evaluating the Efficacy of Transfer Factor TFI Treatment by Assessing the Number of New Infections in Subjects with Recurrent Respiratory or Urinary Tract Infections or Recurrent Herpetic Infections Recorded over a Period of 6 Months from Randomization

2024-516879-32-00 Therapeutic confirmatory (Phase III) Ongoing, recruitment ended

Start 13 Jun 2025 · Status Ongoing, recruitment ended · 1 EU/EEA countries · 3 sites

Overview

Sponsor-declared trial summary

Phase Therapeutic confirmatory (Phase III)
Status Ongoing, recruitment ended
Participants planned 100
Countries 1
Sites 3

• Recurrent respiratory infections • Recurrent urinary tract infections • Recurrent herpetic infections

Key facts

Sponsor
Aumed a.s.
Participant type
Patients
Age range
18-64 years
Gender
Male and Female
Therapeutic area
Diseases [C] - Bacterial Infections and Mycoses [C01], Diseases [C] - Virus Diseases [C02]
Trial duration
13 Jun 2025 → ongoing
Decision date (initial)
2025-01-08
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

• Recurrent respiratory infections • Recurrent urinary tract infections • Recurrent herpetic infections

VersionLevelCodeTermSystem organ class
25.1 LLT 10038133 Recurrent respiratory tract infections 10021881
20.0 HLT 10046577 Urinary tract infections 10021881

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Aumed a.s.

Sponsor organisation
Aumed a.s.
Address
Komoranska 326/63, Modrany Modrany
City
Prague
Postcode
143 00
Country
Czechia

Scientific contact point

Organisation
Aumed a.s.
Contact name
clinical department

Public contact point

Organisation
Aumed a.s.
Contact name
clinical department

Locations

1 EU/EEA country · 3 investigational sites

By country

CountryMS statusPlanned subjectsSites
Czechia Ongoing, recruitment ended 100 3
Rest of world 0

Investigational sites

Czechia

3 sites · Ongoing, recruitment ended
Nemocnice Na Homolce
Oddělení Klinické biochemie, hematologie a imunologie, Roentgenova 37/2, Motol, Prague 5
Fakultni Nemocnice Ostrava
Ustav klinicke imunologie a alergologie, 17. Listopadu 1790/5, Poruba, Ostrava
Fakultni Nemocnice Hradec Kralove
. Depart. Allergology and Clinical Immunology, Sokolska 581, 500 03, Novy Hradec Kralove

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Czechia 2025-06-13 2025-06-13 2026-01-13

Application history

4 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-09-13 Czechia Acceptable
2024-12-12
2025-01-08
2 NON SUBSTANTIAL MODIFICATION NSM-2 2025-12-12 Czechia Acceptable
2024-12-12
2025-12-12
3 SUBSTANTIAL MODIFICATION SM-2 2026-01-20 Czechia Acceptable
2026-02-17
2026-02-17
4 NON SUBSTANTIAL MODIFICATION NSM-3 2026-04-01 Czechia Acceptable
2026-02-17
2026-04-01